Journal
CHEMICAL BIOLOGY & DRUG DESIGN
Volume 99, Issue 5, Pages 736-757Publisher
WILEY
DOI: 10.1111/cbdd.14022
Keywords
anti-tumor agents; benzimidazole; docking; structure unit; target proteins
Funding
- Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study [0223-0002-0002000-44]
- University of South China startup foundation for advanced talent [2018XQD14]
- Jiangxi Provincial Natural Science Foundation [20202BAB212004, 20212BAB202007]
- China Scholarship Council [201908430069]
Ask authors/readers for more resources
This article introduces the benzimidazole as an effective structural unit in drug design and its application in anti-tumor agent research. Further studies have shown that benzimidazole can not only expand the molecular structure but also interact with target proteins or receptors in various ways.
With the development of exploration for disease-related proteins or receptors, more and more novel structural lead compounds are required to designed and synthesized. The benzimidazole is an effective structural unit in which the benzene ring is fused at the 4 and 5 positions of the imidazole ring and wildly used in drug design. Here, we introduce some recent progress of research for anti-tumor agents which was target to various target proteins such as DNA topoisomerase, angiogenesis, serine/threonine protein kinase, and tyrosine protein kinase. These anti-tumor agents are all introduced benzimidazole as the structure unit. Further docking study showed that the benzimidazole group was not only act as a skeleton to expand the structure of molecule but also as an excellent ligand unit to form hydrogen bond or pi-pi conjugation and hydrophobic interaction with target proteins or receptors. We expect that introducing benzimidazole in the chemical structure could be a reasonable and priority strategy in novel anti-tumor agents' design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available